drugset / Trial / NCT00003752

Bexarotene in Treating Patients With Metastatic Breast Cancer

NCT00003752

Phase 2 Completed 180 enrolled Ligand Pharmaceuticals
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of bexarotene in treating patients who have metastatic breast cancer.

Timeline

Start
1998-10
Primary completion
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexarotene Small molecule 200 mg/m2 Oral
Subject Bexarotene Small molecule 500 mg/m2 Oral

Indications